Nuclera, a trailblazing biotechnology company specializing in protein expression and purification, recently raised $75 million in a fresh funding round. This significant financial boost is intended to support the commercialization and global deployment of Nuclera’s eProtein Discovery™ system. The
RNA editing has long been a topic of fascination within the field of genetic research. Recent advancements by Wave Life Sciences have transformed this curiosity into a real-world application, with their trials showing promising results for treating alpha-1 antitrypsin deficiency (AATD). This
Ellorarxine, a groundbreaking drug compound developed by Nevrargenics, is showing remarkable promise in the treatment of Amyotrophic Lateral Sclerosis (ALS) and has recently received approval from the MHRA to advance to human trials. This news brings a glimmer of hope to the over 5,000 individuals
Clinical Outcome Assessments (COAs) play a pivotal role in the drug development process. These tools, which measure the impact of a treatment on patients' health status, encompass several types: Patient-Reported Outcomes (PROs), Clinician-Reported Outcomes (ClinROs), Observer-Reported Outcomes
Lundbeck, the Danish drugmaker, has announced its acquisition of Longboard Pharmaceuticals for $2.6 billion, centering the deal around Longboard's promising experimental brain medicine, bexicaserin. This medicine is in late-stage clinical testing for treating developmental and epileptic
In a significant development for global health preparedness, RedHill Biopharma Ltd. has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to advance opaganib, a promising treatment for Ebola virus disease (EBOV). This collaboration marks a crucial step in combating
